Clinical trial · Interventional
Effect of Weight and Insulin Sensitivity on Reproductive Function in PCOS
NCT01482286CI-TRIAL-00057132PULSEterminatedPhase 3Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Poor recruitment and enrollment.
Summary
Brief summary (as posted)
Polycystic ovary syndrome (PCOS) is the most common reproductive disorder in women of reproductive age and despite decades of research the etiology the disorder is not known. The characteristic hyperandrogenism and anovulation is associated with abnormal neuroendocrine function and insulin resistance. Obesity is a common correlated phenotype of Polycystic ovary syndrome and weight gain worsens the reproductive and metabolic complications. Currently there is no evidence-based treatment plan for infertility in Polycystic ovary syndrome; yet weight loss by dietary restriction and regular exercise are strongly advocated. Weight loss and increased insulin sensitivity appear to drive improvements in reproductive outcomes in women with Polycystic ovary syndrome; however, the mechanism connecting these changes with the reproductive axis is not fully understood.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Polycystic Ovary Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Dietary Restriction | Behavioral | — | UNRESOLVED |
| Exercise Training | Behavioral | — | UNRESOLVED |
| Metformin | Drug | Metformin | ALIAS |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- Metformin
- description
- Subjects randomized to the metformin treatment group will receive 1000 mg extended release metformin hydrochloride tablets (Bristol Myers Squibb) twice per day with food approximately 8 hours apart.
- interventionNames
- Drug: Metformin
- type
- EXPERIMENTAL
- label
- Dietary Restriction
- description
- Subjects randomized to the dietary restriction group (DR) will reduce their energy intake by 25% from their weight maintenance energy intake determined at baseline by doubly labeled water.There will be no gradual ramping of dietary restriction. The 25% energy reduction goal will apply from the first day of the intervention for a period of 24 weeks. Subjects will be asked to not modify their normal level of physical activity.
- interventionNames
- Behavioral: Dietary Restriction
- type
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
- Maximum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria: * 20 - 40 years, inclusive * Body mass index ≥ 25 kg/m2 * History of irregular menstrual cycles (fewer than 6 cycles in the past year) * Clinical and/or biochemical androgen excess (Free androgen index\>3.85 and/or hirsuitism rating ≥8) * Anovulatory menstrual cycles (determined during screening) Exclusion Criteria: * Ovulatory menstrual cycles (determined during screening by luteal phase serum progesterone \>3ng/mL) * History or clinical appearance of cardiovascular disease, diabetes (Type 1 or Type 2) and any other significant reproductive, metabolic, hematologic, pulmonary, gastrointestinal, neurologic, immune, hepatic, renal, urologic disorders, or cancer. * Hemoglobin, hematocrit, red blood cell count, or iron level below the lower limit of normal at the screening visit confirmed by a test repeated within two weeks * Regular use of medications for weight control, glucose intolerance, thyroid disease * Use of hormonal contraception containing medroxyprogesterone acetate (A 3 month washout period will be permitted for oral, vaginal and transdermal contraceptives). Psychiatric and Behavioral Exclusion Criteria * Smoking * History of drug or alcohol abuse (up to 14 drinks a week are allowed) within the past two years * History or presence of an eating disorder as determined by Interview for Diagnosis of Eating Disorders (IDED-IV) * Beck Depression Index (BDI) score of ≥15 at screening or baseline Other Exclusion Criteria * Individuals who have lost more than 5kg (11lbs) in the past 6 months * Individuals who are pregnant or breast-feeding or whom become pregnant during the study * Individuals engaged in a regular program of physical fitness involving some heavy physical activity (e.g., jogging or riding fast on a bicycle for 30 minutes or more) at least five times per week over the past year * Individuals who have metallic objects in their body * Individuals who donated blood within 30 days prior to the date of randomization * Individuals unwilling to be assigned at random to either one of the intervention groups * Unwilling or unable to adhere to the rigors of the data collection (determined by food and activities diaries at screening, see below) and clinical evaluation schedule over the entire 24 week intervention period * Individuals who plan to move out of the area within the next 12 months or plan to be out of the study area for more than 4 weeks in the next 12 months * Individuals who reside too far from Pennington
References
Publications (2)
- DERIVEDBroskey NT, Tam CS, Sutton EF, Altazan AD, Burton JH, Ravussin E, Redman LM. Metabolic inflexibility in women with PCOS is similar to women with type 2 diabetes. Nutr Metab (Lond). 2018 Oct 20;15:75. doi: 10.1186/s12986-018-0312-9. eCollection 2018. PMID 30377436
- DERIVEDBroskey NT, Klempel MC, Gilmore LA, Sutton EF, Altazan AD, Burton JH, Ravussin E, Redman LM. Assessing Energy Requirements in Women With Polycystic Ovary Syndrome: A Comparison Against Doubly Labeled Water. J Clin Endocrinol Metab. 2017 Jun 1;102(6):1951-1959. doi: 10.1210/jc.2017-00459. PMID 28323951